Humanized anti-CD4 antibody with immunosuppressive properties
A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
1. A method of treating a subject suffering from an autoimmune disease comprising administering to said subject an antibody, wherein said antibody is a humanized anti-CD4 antibody, wherein the humanized antibody comprises the complementarity-determining regions (CDRs) of SEQ ID NOs: 10 and 9, displayed in FIGS. 3 and 4 ,
and wherein the humanized anti-CD4 antibody is capable of activating CD4 + CD25 + regulatory T cells such that the activated CD4 + CD25 + regulatory T cells are able to suppress CD4 + CD45RA+CD25− T cell proliferation in vitro in an allogenic mixed lymphocyte reaction in which the activated CD4 + CD25 + regulatory T cells are cocultured with allogenic CD4 + CD45RA+CD25− T cell in the presence of CD2-depleted peripheral blood mononuclear cells that are syngenic for the CD4 + CD25 + regulatory T cells.
2. A method according to claim 1 wherein the humanized anti-CD4 antibody which is capable of activating CD4 + CD25 + regulatory T cells comprises a V domain comprising SEQ ID No: 1 and a V domain comprising SEQ ID No: 2.
3. A method according to claim 1 wherein the autoimmune disease is selected from the group consisting of: myocarditis, type I diabetes, psoriasis, lupus erythematosus, Crohn's disease, multiple sclerosis, rheumatoid arthritis, ulcerative colitis and atopic dermatitis.
4. A method according to claim 1 wherein the autoimmune disease is psoriasis.
5. A method according to claim 1 wherein the autoimmune disease is rheumatoid arthritis.
6. A method of treating a subject suffering from an autoimmune disease comprising administering to said subject a humanized anti-CD4 antibody, wherein said antibody comprises an H chain V domain comprising SEQ ID No: 1 and an L chain V domain comprising SEQ ID No: 2.